Fish, M.
Rynne, J.
Jennings, A.
Lam, C.
Lamikanra, A. A.
Ratcliff, J.
Cellone-Trevelin, S.
Timms, E.
Jiriha, J.
Tosi, I.
Pramanik, R.
Simmonds, P.
Seth, S.
Williams, J.
Gordon, A. C.
Knight, J.
Smith, D. J.
Whalley, J.
Harrison, D.
Rowan, K.
Harvala, H.
Klenerman, P.
Estcourt, L.
Menon, D. K.
Roberts, D.
Shankar-Hari, M. http://orcid.org/0000-0002-5338-2538
,
Funding for this research was provided by:
National Institute for Health Research (COV19-RECPLAS)
Article History
Received: 12 July 2022
Accepted: 11 August 2022
First Online: 14 September 2022
Declarations
:
: LE reported receiving grants from the National Institute for Health Research and European Union Horizon 2020. ACG reported receiving grants from the National Institute for Health Research and receiving personal fees from 30 Respiratory, GlaxoSmithKline, and Bristol Myers Squibb. DKM reports consultancy agreements, educational support, or research collaborations with NeuroTrauma Sciences LLC, GlaxoSmithKline Ltd, Calico Ltd, Lantmannen AB, Cortirio Ltd, and Gryphon Inc., all outside the research in this manuscript. MSH reports receiving grant from the Chief Scientists Office, Scotland, for time-critical precision medicine in adult critically ill patients (TRAITS Programme) and highlights industry support for TRAITS research programme (ExternalRef removed).
Free to read: This content has been made available to all.